bromodeoxyuridine has been researched along with Gastrointestinal Stromal Tumors in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, MK; Horowitz, JC; Moore, BB; Thannickal, VJ; Vittal, R; Zhang, H | 1 |
1 other study(ies) available for bromodeoxyuridine and Gastrointestinal Stromal Tumors
| Article | Year |
|---|---|
Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Benzamides; Bleomycin; Blotting, Western; Bromodeoxyuridine; Caspase 3; Cell Line, Tumor; Cells, Cultured; Collagen; DNA, Single-Stranded; Dose-Response Relationship, Drug; Epithelial Cells; Fibroblasts; Fibrosis; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indicators and Reagents; Injections, Intraperitoneal; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases; Mesenchymal Stem Cells; Mice; Phenotype; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction | 2007 |